Are Mannan-binding Lectine Serin Protease-2 and Alpha-1-microglobulin and Bukinin Precursor the Potential Biomarkers of Manic Episode? A Study via Urinary Proetomic Analysis

다국어 초록 (Multilingual Abstract)

Objective: Investigating the molecular basis of bipolar disorder (BD) is crucial in terms of developing effective treatment strategies as well as objective laboratory-based diagnostic tools for the disease.
Methods: We examined the urine samples of BD patients both in manic episode and after remission and compared their urinary protein profiles with the controls. Twelve patients and twelve controls (C group) included to the study.
Urinary samples of patients were first collected during manic episode (M group) and then after remission (R group).
Two-dimensional gel electrophoresis (2-DE) coupled to MALDI-TOF/TOF massspectrometry approach and Western blot analysis were used.
Results: Alpha-1-microglobulin and bukinin precursor (AMBP), Mannan-binding lectine serin protease-2 (MASP-2), and Ig gamma-1-chain displayed significant increases in their abundance in the urine protein pool of M group in comparison to the C and R groups. Alpha-1B glycoprotein and prostaglandin-H2 D-isomerase (PGD2) levels were significantly higher in the urine protein pool of the M and R groups in comparison to the C group. Annexin A1 was downregulated significantly in the urine protein pool of the M group in comparison to the C group.
Conclusion: Intensities of MASP-2 and AMBP proteins discriminated manic episode from remission period and healthy controls indicating that these proteins may be candidate biomarkers for manic episode. The decrease in Annexin A1 and increase in Ig gamma-1 chain levels appeared to be associated with “Manic Episode” while the increase in PGD2 and alpha-1B glycoprotein levels appeared to be associated with “Bipolar Disorder”.

참고문헌 (Reference)

1 Wang Y, "Urinary peptidomics identifies potential biomarkers for major depressive disorder" 217 : 25-33, 2014

2 An M, "Urinary biomarkers of brain diseases" 13 : 345-354, 2015

3 Bartoli F, "Update on bipolar disorder biomarker candidates: what about uric acid/adenosine hypothesis?" 17 : 105-106, 2017

4 Teixeira AL, "Update on bipolar disorder biomarker candidates" 16 : 1209-1220, 2016

5 Kupfer DJ, "The increasing medical burden in bipolar disorder" 293 : 2528-2530, 2005

6 Woo JJ, "The complement system in schizophrenia: where are we now and what's next?" 25 : 114-130, 2020

7 Iria Grande, "The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder" 대한신경정신의학회 7 (7): 243-250, 2010

8 Kidmose RT, "Structural basis for activation of the complement system by component C4 cleavage" 109 : 15425-15430, 2012

9 Szklarczyk D, "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets" 47 : D607-, 2019

10 Chengappa KN, "Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania" 5 : 1-5, 2003

11 Pieper R, "Preparation of urine samples for proteomic analysis" 425 : 89-99, 2008

12 Butler TAJ, "Misleading westerns : common quantification mistakes in Western blot densitometry and proposed corrective measures" 2019 : 5214821-, 2019

13 Maffioletti E, "Micro spies from the brain to the periphery : new clues from studies on microRNAs in neuropsychiatric disorders" 8 : 75-, 2014

14 Zhang R, "Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls" 14 : 106-116, 2016

15 Foldager L, "MBL and MASP-2 concentrations in serum and MBL2promoter polymorphisms are associated to schizophrenia" 24 : 199-207, 2012

16 Sandberg JV, "Low neuropeptide Y in cerebrospinal fluid in bipolar patients is associated with previous and prospective suicide attempts" 24 : 1907-1915, 2014

17 Monfrim X, "Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β?" 16 : 741-747, 2014

18 Biswas S, "Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach" 8 : e56246-, 2013

19 Kanli A, "Identification of differentially regulated deceitful proteins in SH-SY5Y cells engineered with Tet-regulated protein expression system" 119 : 6065-6071, 2018

20 Menezes IC, "Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder : a systematic and critical review" 357-358 : 29-38, 2019

21 Berk M, "From neuroprogression to neuroprotection : implications for clinical care" 193 (193): S36-S40, 2010

22 Frye MA, "Feasibility of investigating differential proteomic expression in depression : implications for biomarker development in mood disorders" 5 : e689-, 2015

23 Moore GL, "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions" 2 : 181-189, 2010

24 Patel JP, "Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder?" 2015 : 708306-, 2015

25 Johnston-Wilson NL, "Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium" 5 : 142-149, 2000

26 Bellei E, "Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis" 8 : e01062-, 2018

27 Marín-Méndez JJ, "Differential expression of prostaglandin D2synthase(PTGDS)in patients with attention deficit-hyperactivity disorder and bipolar disorder" 138 : 479-484, 2012

28 McIntyre RS, "Differential diagnosis of major depressive disorder versus bipolar disorder:current status and best clinical practices" 80 : ot18043ah2-, 2019

29 Bayes A, "Differential diagnosis of bipolar II disorder and borderline personality disorder" 21 : 125-, 2019

30 de Oliveira GS, "Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients" 43 : 1171-1174, 2009

31 Jacoby AS, "Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder-Results from a prospective study" 197 : 167-174, 2016

32 Munkholm K, "Cytokines in bipolar disorder : a systematic review and meta-analysis" 144 : 16-27, 2013

33 Yoshimi N, "Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder : evidence in support of mitochondrial dysfunction hypothesis" 21 : 1504-1510, 2016

34 Ditzen C, "Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology" 37 : 1013-1025, 2012

35 Rolstad S, "CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment" 25 : 1091-1098, 2015

36 Duncan RE, "Brain arachidonic acid uptake and turnover : implications for signaling and bipolar disorder" 13 : 130-138, 2010

37 Foldager L, "Bipolar and panic disorders may be associated with hereditary defects in the innate immune system" 164 : 148-154, 2014

38 Leoni G, "Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair" 125 : 1215-1227, 2015

39 Gussenhoven R, "Annexin A1 as neuroprotective determinant for blood-brain barrier integrity in neonatal hypoxic-ischemic encephalopathy" 8 : 137-, 2019

40 Perretti M, "Annexin A1 and glucocorticoids as effectors of the resolution of inflammation" 9 : 62-70, 2009

41 Bruschi M, "Annexin A1 and autoimmunity : from basic science to clinical applications" 19 : 1348-, 2018

42 Gertow J, "Altered protein composition of subcutaneous adipose tissue in chronic kidney disease" 2 : 1208-1218, 2017

43 Zager RA, "Alpha 1 microglobulin : a potentially paradoxical anti-oxidant agent" 5 : 238-, 2017

44 Gurvich A, "A role for prostaglandins in rapid cycling suggested by episode-specific gene expression shifts in peripheral blood mononuclear cells : a preliminary report" 16 : 881-888, 2014

45 Beck A, "8th Annual european antibody congress 2012- Nov 27-28, 2012, Geneva, Switzerland" 5 : 339-357, 2013